Recently, Jiangsu Province Pharmaceutical Medical Consumables Sunshine Procurement Service Network issued a drug warning for April 2023, and a number of varieties were suspended from listing on the network because the price difference was more than 10 times and were rated as "red three-star".
In 2021, the Jiangsu Provincial Medical Insurance Bureau issued the Implementation Opinions on In-depth Promotion of Drug Sunshine Procurement, and the implementation opinions proposed to dynamically monitor the prices of drugs listed on the provincial sunshine procurement platform and timely discover abnormal disposal prices.
Price early warning management shall be implemented for newly listed drugs, of which:
(1) If the price is 10 times (inclusive) or more than the highest price of the same variety that has been listed on the net (hereinafter referred to as the highest price on the network) at the time of the implementation of the sunshine procurement system, it will be marked as a red warning ★★★, and the product trading qualification will be suspended, and medical institutions shall not purchase in principle;
(2) If the price is 2 times (inclusive) -5 times and 5 times (inclusive)-10 times the highest price of the listed network, it shall be marked as a red alert and a red alert ★ ★★ respectively, and relevant enterprises shall be interviewed to remind medical institutions to purchase cautiously;
(3) If the price is higher than the highest price on the network but less than 2 times, it will be marked with a yellow warning to remind the medical institution.
For drugs that are re-listed after the network is removed, and there are no products of the same variety that have been connected to the network, the price before the withdrawal of the network is 1.8 times the highest price of the network, and price early warning management is carried out.
The price warning implements dynamic management, and the early warning mark is updated at the beginning of every quarter, encouraging enterprises to take the initiative to adjust the price of the hanging network to a reasonable range. For drugs included in the scope of price warning, focus on strengthening price negotiation and procurement monitoring; Medical security departments are to interview and urge rectification of medical institutions that rank high in the quantity and amount of procurement of early warning drugs, and report serious cases to the discipline inspection and supervision department at the same level.
While reducing the price of products such as centralized procurement, the synchronous governance of the prices of drugs listed on the Internet has also become the focus of supervision. Unifying the work processes and rules of the provinces has become the focus of repeated policy mentions.
In 2020, the National Health Insurance Administration stated in the "Letter on the Response to the Proposal No. 3778 (Cai, Taxation and Finance No. 276) of the Third Session of the 13th National Committee of the Chinese People's Political Consultative Conference" that it would further strengthen the standardization of the operation of the centralized drug procurement platform, establish and improve unified basic operating rules, and further standardize the work process and the rules for drug listing and disconnection.
In 2021, the "Opinions of the General Office of the State Council on Promoting the Normalization and Institutionalization of Centralized Drug Procurement Work" was issued, requiring strengthening the standardization of centralized drug procurement platforms, unifying basic operating rules, work processes and standards for drug disconnection, unifying medical insurance drug classification and codes, unifying drug procurement information standards, realizing the interconnection and interoperability of interprovincial drug centralized procurement information, and accelerating the formation of a unified and open national centralized drug procurement market.
This year, according to the work focus of the National Medical Insurance Administration Centralized Procurement Center circulated in the pharmaceutical circle, it is clear that it will formulate unified network listing rules for provincial platforms, optimize the network listing process, adhere to the integration of recruitment and procurement, volume and price listing, quality and price matching, and further promote the deepening of the reform of the centralized procurement system to develop in depth. In order to improve the linkage and integrity of the national centralized procurement market, the functions of local systems will be gradually standardized, so as to form a relatively unified functional system, and guide all localities to rely on the procurement subsystem to carry out procurement, trading, settlement and other work.
Of particular concern is the formulation of provincial-level unified rules for hanging the network. In the document, the price procurement center proposed that "one stop on the bus, the whole country passes". It seems that the implication is that as long as it is reviewed once, it can be listed on the network nationwide, which will undoubtedly reduce the difficulty of managing drugs on the network in various provinces, and also greatly reduce the work of pharmaceutical companies on the network. At the same time, for pharmaceutical companies, the era of national unification of drug prices has come: there will be a price management in the future.
